Gemogenovatucel-T is under clinical development by Gradalis and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase II drugs for Metastatic Melanoma have a 34% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Gemogenovatucel-T’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gemogenovatucel-T (Vigil) is under development for the treatment of solid tumors including Ewing sarcoma, uterine cancer, cervical cancer, endometrioid cancer, ovarian cancer, fallopian tube cancer or primary peritoneal cancer, non-small cell lung cancer, primitive neuroectodermal tumor, thyroid cancer, metastatic melanoma, hepatocellular carcinoma and colorectal cancer. The vaccine candidate is administered intradermally. The immunotherapy consists of autologous cells expressing rhGMCSF and bi-shRNAfurin from the FANG plasmid.
It was also under development for the treatment of Ewing sarcoma, uterine cancer, cervical cancer, neuroendocrine tumors, colorectal cancer with liver metastases and triple negative breast cancer.
Gradalis formerly Murex Pharmaceuticals is a biotechnology company that develops and commercializes novel therapies for the treatment of cancer. The company’s product pipeline includes autologous cancer vaccines, IO combinations and genes proteins for treating Ewing’s sarcoma, ovarian, breast, melanoma, solid tumors, lung, hepatocellular and colorectal cancer. Its proprietary immunotherapy platform, vigil is utilized in various advanced cancer indications and helps in stimulating and improving the body’s natural mechanism for identifying and killing cancer cells. Gradalis is headquartered in Carrollton, Texas, the US.
For a complete picture of Gemogenovatucel-T’s drug-specific PTSR and LoA scores, buy the report here.